



# Report on antimalarial drug efficacy, resistance and response



**years of surveillance (2010–2019)**





# Report on antimalarial drug efficacy, resistance and response



**years of surveillance (2010–2019)**



# Contents

<b>Acknowledgements</b>	<b>v</b>
<b>Abbreviations and acronyms</b>	<b>vi</b>
<b>Executive summary</b>	<b>vii</b>
<b>1. Introduction</b>	<b>1</b>
<b>2. Antimalarial treatment</b>	<b>1</b>
2.1 WHO-recommended treatments for malaria	1
2.2 Other recommended use of antimalarial medicine	2
<b>3. Antimalarial drug resistance</b>	<b>3</b>
3.1 Defining antimalarial drug resistance	3
3.2 Artemisinin partial resistance	4
3.3 Global public health implications of antimalarial drug resistance	5
3.4 Responding to the global threat of resistance	6
<b>4. Tools for monitoring antimalarial drug efficacy and drug resistance</b>	<b>9</b>
4.1 Therapeutic efficacy studies	9
4.1.1 TES for <i>P. falciparum</i>	9
4.1.2 Classification of recurrent <i>P. falciparum</i> infections	12
4.1.3 <i>P. falciparum</i> TES in different settings	12
4.1.4 TES for <i>P. vivax</i> and <i>P. ovale</i>	13
4.1.5 Frequent deviations from the WHO TES standard protocol	17
4.2 Integrated drug efficacy surveillance	18
4.3 Evaluating the cause of treatment failure	19
4.3.1 Studies of drug blood levels	19
4.3.2 In vitro and ex vivo tests	19
4.3.3 Molecular markers	21
4.4 Informing policy change	24

<b>5. Data on antimalarial drug efficacy and drug resistance (2010–2019)</b>	<b>25</b>
<b>5.1</b> Summary	25
<b>5.2</b> WHO African Region	27
<b>5.2.1</b> WHO African Region: Central Africa	27
<b>5.2.2</b> WHO African Region: Eastern and Southern Africa	29
<b>5.2.3</b> WHO African Region: West Africa	30
<b>5.3</b> WHO Region of the Americas	32
<b>5.4</b> WHO South-East Asia Region	34
<b>5.5</b> WHO Eastern Mediterranean Region	37
<b>5.6</b> WHO Western Pacific Region	39
<b>5.7</b> Other species	42
<b>References</b>	<b>44</b>
<b>Annex 1:</b> Countries where <i>Plasmodium vivax</i> chloroquine failure or resistance was reported	51
<b>Annex 2:</b> Summary of treatment failure rates grouped by species, treatment, country and WHO region	52
<b>Annex 3:</b> Countries by WHO regions and inter-country support teams	63

## ACKNOWLEDGEMENTS

This document was prepared for the World Health Organization (WHO) Global Malaria Programme (GMP) by Charlotte Rasmussen and Pascal Ringwald, with the support of Amy Barrette and Lucia Fernandez Montoya (for the management of the database and the threats maps). WHO/GMP wishes to thank Kevin Baird, Leonardo Kishi Basco, Maria Dorina Bustos, Laurence Slutsker and Mariam Warsame for their deep review of the document and helpful suggestions. WHO/GMP also acknowledges the comments made by the regional advisors and colleagues from the regions: Elisabeth Juma, Akpaka Kalu, James Kelly, Roberto Montoya, Spes Caritas Ntabangana, Risintha Gayan Premaratne, Abderahmane Kharchi Tfeil, Maria de la Paz Ade y Torrent, Neena Nee Kesar Valecha and Ghasem Zamani. WHO/GMP wishes to thank the ministries of health, nongovernmental organizations, pharmaceutical companies, public private partnerships, research institutes, collaboratives centres, subregional networks and WHO regional offices that kindly shared their data. Financial support for the preparation of this document and the database was provided by the Bill & Melinda Gates Foundation. The final draft was edited by Cadman Editing Services, Australia.

## ABBREVIATIONS AND ACRONYMS

<b>ACPR</b>	adequate clinical and parasitological response
<b>ACT</b>	artemisinin-based combination therapy
<b>AL</b>	artemether-lumefantrine
<b>AQ</b>	amodiaquine
<b>AS</b>	artesunate
<b>AUC</b>	area under the plasma drug concentration curve
<b>CQ</b>	chloroquine
<b>DHA</b>	dihydroartemisinin
<b>ETF</b>	early treatment failure
<b>G6PD</b>	glucose-6-phosphate dehydrogenase
<b>GMP</b>	Global Malaria Programme
<b>GMS</b>	Greater Mekong subregion
<b>GPARC</b>	Global Plan for Artemisinin Resistance Containment
<b>HIV</b>	human immunodeficiency virus
<b>iDES</b>	integrated drug efficacy surveillance
<b>IPTi</b>	intermittent preventive treatment of infants
<b>IPTp</b>	intermittent preventive treatment of pregnant women
<b>LCF</b>	late clinical failure
<b>LPF</b>	late parasitological failure
<b>MDA</b>	mass drug administration
<b>MQ</b>	mefloquine
<b>PCR</b>	polymerase chain reaction
<b><i>Pfcr1</i></b>	<i>P. falciparum</i> chloroquine resistance transporter
<b><i>Pfcy1b</i></b>	<i>P. falciparum</i> cytochrome <i>b</i>
<b><i>Pfdhfr</i></b>	<i>P. falciparum</i> dihydrofolate reductase
<b><i>Pfdhps</i></b>	<i>P. falciparum</i> dihydropteroate synthase
<b><i>PfK13</i></b>	<i>P. falciparum</i> Kelch 13
<b><i>Pfmdr1</i></b>	<i>P. falciparum</i> multidrug resistance 1 protein
<b><i>Pfpm 2–3</i></b>	<i>P. falciparum</i> plasmepsin 2–3
<b>PPQ</b>	piperaquine
<b>PQ</b>	primaquine
<b><i>Pvcrt-o</i></b>	<i>P. vivax</i> chloroquine resistance transporter
<b><i>Pvdhfr</i></b>	<i>P. vivax</i> dihydrofolate reductase
<b><i>Pvdhps</i></b>	<i>P. vivax</i> dihydropteroate synthase
<b><i>Pvmdr1</i></b>	<i>P. vivax</i> multidrug resistance 1 protein
<b>PSA</b>	piperaquine survival assay
<b>PY</b>	pyronaridine
<b>RSA</b>	ring-stage survival assay
<b>SMC</b>	seasonal malaria chemoprevention
<b>SP</b>	sulfadoxine-pyrimethamine
<b>TEC</b>	therapeutic efficacy studies

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24255](https://www.yunbaogao.cn/report/index/report?reportId=5_24255)

